溯源性时代的内部质量控制
本文讨论在检验结果需溯源至高级参考物的背景下,医学实验室应如何重新设计室内质控(IQC)程序。提出IQC应分为两部分:组件I验证配套控制品是否在临床适用范围内以监视IVD溯源性;组件II估计随机效应引入的测量不确定度(MU)并监测系统可靠性。
要点
- IQC组件I用于验证厂家配套控制品是否在临床适用验证范围内。
- IQC组件II用于估计随机效应MU并监测测量系统可靠性。
- 性能恶化时应及时采取纠正措施以保障结果临床有效性。
核心结论
- 室内质控程序应重新设计以支持IVD溯源性监视和测量不确定度评估。
关键数值与推荐
- IQC组件I通过验证厂家提供的控制品是否在临床适用验证范围内来监视溯源性。
- IQC组件II致力于估计随机效应引起的MU并获得提供结果的MU。
临床怎么用
- 实验室应了解并验证厂家如何实现校准品溯源性并估计临床样本的MU。
- 实验室应分别实施IQC组件I和组件II以监视溯源性和系统可靠性。
- 当性能相比适当分析规范恶化时应采取及时纠正措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To be accurate and equivalent, laboratory results should be traceable to higher-order references. Furthermore, their quality should fulfill acceptable measurement uncertainty (MU) as defined to fit the intended clinical use. With this aim, in vitro diagnostics (IVD) manufacturers should define a calibration hierarchy to assign traceable values to their system calibrators. Medical laboratories should know and verify how manufacturers have implemented the traceability of their calibrators and estimate the corresponding MU on clinical samples. Accordingly, the internal quality control (IQC) program should be redesigned to permit IVD traceability surveillance through the verification by medical laboratories that control materials, provided by the manufacturer as a part of measuring systems, are in the clinically suitable validation range (IQC component I). Separately, laboratories should also monitor the reliability of employed IVD measuring systems through the IQC component II, devoted to estimation of MU due to random effects and to obtaining MU of provided results, in order to apply prompt corrective actions if the performance is worsening when compared to appropriate analytical specifications, thus jeopardizing the clinical validity of test results.
引用
- Braga F, Pasqualetti S, Aloisio E, et al. The internal quality control in the traceability era. Clin Chem Lab Med. 2020. PMID: 32639119. doi:10.1515/cclm-2020-0371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。